We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: beta-blockers
MedXY News
EnglishTag

beta-blockers

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Validated Risk Stratification for RYR2-Mediated Catecholaminergic Polymorphic Ventricular Tachycardia on Beta-Blocker Therapy
Cardiologyrisk stratificationCPVT

Validated Risk Stratification for RYR2-Mediated Catecholaminergic Polymorphic Ventricular Tachycardia on Beta-Blocker Therapy

By MedXY|Sep 6, 2026

This article reviews a validated clinical risk model predicting arrhythmic events in patients with RYR2-mediated CPVT receiving beta-blockers, facilitating personalized management to reduce life-threatening arrhythmias.

Unraveling the Mortality Benefits of Beta-Blockers in COPD Patients with Cardiovascular Disease: Influence of LABA Co-therapy
Cardiologycardiovascular disease
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
COPD

Unraveling the Mortality Benefits of Beta-Blockers in COPD Patients with Cardiovascular Disease: Influence of LABA Co-therapy

By MedXY|Aug 12, 2026

A large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.

Higher Resting Heart Rate Still Signals Risk After Myocardial Infarction, and Stopping β-Blockers Raises Heart Rate Without Identifying a Safe Subgroup
Cardiologybeta-blockersheart rate

Higher Resting Heart Rate Still Signals Risk After Myocardial Infarction, and Stopping β-Blockers Raises Heart Rate Without Identifying a Safe Subgroup

By MedXY|Jun 10, 2026

A secondary analysis of ABYSS shows that in stable post-MI patients with preserved ejection fraction, higher heart rate remains prognostic and β-blocker interruption increases heart rate by about 10–13 bpm while worsening outcomes across he

Revisiting Pharmacotherapy in Nonobstructive Hypertrophic Cardiomyopathy: Insights from a Randomized Triple-Crossover Trial of Bisoprolol vs. Verapamil
Cardiologybeta-blockersclinical trials

Revisiting Pharmacotherapy in Nonobstructive Hypertrophic Cardiomyopathy: Insights from a Randomized Triple-Crossover Trial of Bisoprolol vs. Verapamil

By MedXY|Mar 6, 2026

A pivotal triple-crossover RCT reveals that while bisoprolol reduces exercise capacity and worsens diastolic markers in nonobstructive HCM, verapamil maintains exercise performance and improves myocardial strain.

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials
Cardiologybeta-blockersmyocardial infarction

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials

By MedXY|Nov 10, 2025

An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indicati

Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses
Cardiologybeta-blockersmyocardial infarction

Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses

By MedXY|Oct 6, 2025

Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy conside

Safety of Beta Blocker Withdrawal After Myocardial Infarction Without Reduced Ejection Fraction: Insights from the REBOOT Trial Post Hoc Analysis
Cardiologybeta-blockersleft ventricular ejection fraction

Safety of Beta Blocker Withdrawal After Myocardial Infarction Without Reduced Ejection Fraction: Insights from the REBOOT Trial Post Hoc Analysis

By MedXY|Oct 6, 2025

Post hoc analysis of the REBOOT trial shows that withholding or withdrawing beta blockers after myocardial infarction in patients with preserved LVEF (>40%) does not increase short-term or recurrent ischaemic events, challenging current

Sex-Specific Outcomes of Beta-Blocker Therapy After Myocardial Infarction: Insights from the REBOOT Trial
Cardiologybeta-blockersLVEF

Sex-Specific Outcomes of Beta-Blocker Therapy After Myocardial Infarction: Insights from the REBOOT Trial

By MedXY|Oct 6, 2025

The REBOOT trial reveals a sex-specific differential effect of beta-blockers after MI, showing increased harm in women with preserved LVEF, challenging current guideline recommendations.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities